BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38138277)

  • 1. Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma.
    Lee M; Shin HP
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138277
    [No Abstract]   [Full Text] [Related]  

  • 2. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
    Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
    Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
    Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
    Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
    Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
    Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
    World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
    Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
    Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.